Previous Article | Next Article 
Journal of Bacteriology, September 2000, p. 5091-5096, Vol. 182, No. 18
0021-9193/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Metronidazole Activation Is Mutagenic and Causes
DNA Fragmentation in Helicobacter pylori and in
Escherichia coli Containing a Cloned H. pylori
rdxA+ (Nitroreductase) Gene
Gary
Sisson,1
Jin-Yong
Jeong,2
Avery
Goodwin,1
Louis
Bryden,1
Norma
Rossler,1
Sabrina
Lim-Morrison,1
Ausra
Raudonikiene,1
Douglas E.
Berg,2 and
Paul S.
Hoffman1,3,*
Department of Microbiology and
Immunology1 and Division of Infectious
Diseases, Department of Medicine,3 Dalhousie
University, Halifax, Nova Scotia, Canada, and Department of
Molecular Microbiology and Department of Genetics, Washington
University School of Medicine, St. Louis, Missouri2
Received 23 March 2000/Accepted 28 June 2000
 |
ABSTRACT |
Much of the normal high sensitivity of wild-type Helicobacter
pylori to metronidazole (Mtz) depends on rdxA
(HP0954), a gene encoding a novel nitroreductase that catalyzes the
conversion of Mtz from a harmless prodrug to a bactericidal agent. Here
we report that levels of Mtz that partially inhibit growth stimulate forward mutation to rifampin resistance in
rdxA+ (Mtzs) and also in
rdxA (Mtzr) H. pylori strains, and
that expression of rdxA in Escherichia coli
results in equivalent Mtz-induced mutation. A reversion test using
defined lac tester strains of E. coli carrying
rdxA+ indicated that CG-to-GC transversions and
AT-to-GC transitions are induced more frequently than other base
substitutions. Alkaline gel electrophoretic tests showed that Mtz
concentrations near or higher than the MIC for growth also caused DNA
breakage in H. pylori and in E. coli carrying
rdxA+, suggesting that this damage may account
for most of the bactericidal action of Mtz. Coculture of
Mtzs H. pylori with E. coli (highly
resistant to Mtz) in the presence of Mtz did not stimulate forward
mutation in E. coli, indicating that the mutagenic and
bactericidal products of Mtz metabolism do not diffuse significantly to
neighboring (bystander) cells. Our results suggest that the widespread
use of Mtz against other pathogens in people chronically infected with
H. pylori may stimulate mutation and recombination in
H. pylori, thereby speeding host-specific adaptation, the
evolution of virulence, and the emergence of resistance against Mtz and
other clinically useful antimicrobials.
 |
INTRODUCTION |
Metronidazole (Mtz)
[1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole] and related
5-nitroimidazoles are redox-active prodrugs that are often used to
treat infections caused by anaerobic bacteria and protozoa (7, 18,
28). They are also a key component of combination therapies that
are used to eradicate Helicobacter pylori, the
microaerophilic bacterium which chronically infects the stomachs of
more than half of all people worldwide and is the major cause of peptic
ulcer disease and an early risk factor for gastric cancer (3, 14,
20, 30). In anaerobes, redox-active enzymes such as
pyruvate/ketoacid oxidoreductases and hydrogenase, active with the
low-redox carriers (ferredoxin and flavodoxin), reduce
5-nitroimidazoles to mutagenic products that also cause DNA helix
destabilization and single- and double-strand DNA breakage (7, 18,
19, 28). High-level Mtz resistance is rare in anaerobes, because
the activating enzymes are essential components of core metabolic
pathways and because these microbes generally contain cytoplasmic
components of very low redox potential that can spontaneously activate
the drug (7, 19, 23, 28). In contrast, moderate to
high-level resistance to nitroimidazoles is common among H. pylori clinical isolates, with frequencies ranging from ~10 to
90% or more of strains, depending on geographic region
(12). These frequencies generally reflect the incidence of
Mtz usage against other (parasitic or anaerobic bacterial) infections
in particular societies (6, 10).
We have found that (i) nearly all Mtz-resistant (Mtzr)
H. pylori clinical isolates contain loss-of-function
mutations in rdxA (HP0954 in reference
27), an H. pylori gene that encodes a
nonessential oxygen-insensitive NADPH nitroreductase (RdxA); (ii)
mutational inactivation of rdxA is both necessary and
sufficient to confer an Mtzr phenotype; and (iii)
expression of the H. pylori rdxA+ gene in
E. coli renders this normally Mtzr bacterium
susceptible to Mtz (5, 9, 17). Several other studies have
confirmed an association between loss-of-function mutations in
rdxA and Mtz resistance (15, 26). RdxA, a homolog of the classical nitroreductases of enteric bacteria, exhibits NADPH-dependent Mtz reductase activity and a substrate preference for
Mtz that may be related to its unique cysteine-rich nature and alkaline
pI (9). The stoichiometry of the RdxA-catalyzed reduction of
Mtz indicates an anaerobic two-step (four-electron) reduction of the
5-nitro group of Mtz to mutagenic and DNA-damaging nitroso and
hydroxylamine products. Although the DNA sequences of rdxA
genes from unrelated strains typically differed at some 5% of
nucleotide positions (as is quite typical of housekeeping genes in
H. pylori), the rdxA genes from related
Mtzr and Mtzs strains recovered from infections
that were mixed (Mtzr, Mtzs), but uniform in
overall DNA fingerprint type, differed by only one or a few base pairs.
This indicated that Mtz resistance tends to result from de novo
mutation in the resident rdxA gene, rather than from lateral
transfer of mutant rdxA (or other) genes from unrelated but
Mtzr strains. Equivalent results were obtained with a dozen
patients from France and North Africa (26). These findings
suggested that Mtz-based therapies might be mutagenic, inducing as well as selecting for Mtz resistance in H. pylori (9).
Here we show directly that products of Mtz activation are mutagenic and
DNA damaging in H. pylori and in Escherichia coli containing a cloned rdxA+ gene. These findings
have implications for the emergence of resistance to various
antibacterial agents and more generally to the evolution of virulence
and the adaptation of H. pylori to individual hosts.
 |
MATERIALS AND METHODS |
Bacterial strains and DNA manipulations.
H. pylori
Mtzs strains 950 and 1134 and Mtzr strain 1134R
have been described elsewhere (9). Strain 26695 (27) and its Mtzr (rdxA deletion
mutant) derivatives 16R and 64R (carrying null mutations in
rdxA and in rdxA and frxA; resistant
to Mtz at 16 and 64 µg/ml, respectively) are described elsewhere
(17). All H. pylori strains were cultured under
microaerobic conditions on either Brucella agar supplemented
with 7.5% newborn calf serum (NCS; Sigma) (9, 13) or brain
heart infusion (BHI) agar with horse blood (17). E. coli strains CC101, CC103, CC104, CC105, and CC106
[ara
(lac proB)/F' lacI lacZ
proAB+) contain mutations in lacZ that
render them unable to ferment lactose (4). The
rdxA gene from H. pylori strain 950 was amplified by PCR using previously described rdxA oligonucleotide
primers (9) and cloned into the pBluescript (pBSK) cloning
vector plasmid, creating pGS950. E. coli strains expressing
RdxA nitroreductase are susceptible to Mtz (10 to 30 µg/ml) when
tested on Luria-Bertani (LB) medium (9).
Mtz-induced mutation in H. pylori:
Rifr.
New mutations to rifampin resistance
(Rifr) which result from changes in rpoB
(11) were quantified as a measure of Mtz-induced mutation in
H. pylori. Frozen cultures of isogenic Mtzs and
Mtzr strains of H. pylori (26695, 16R, and 64R)
were streaked onto BHI blood agar plates and incubated for 3 days.
Individual colonies were respread on fresh medium without Mtz and
incubated for 3 days; then 107 to 108 bacterial
cells were spread onto BHI blood agar plates containing various
concentration of Mtz (0, 1, 2, and 3 µg/ml for 26695 (wild type); 0, 3, 8, 16, 25, and 32 µg/ml for 16R; 0, 8, 16, 32, and 90 µg/ml for
64R). Following 3 days of incubation, bacterial cells were suspended in
phosphate-buffered saline, and spread on BHI blood agar with rifampin
(5 µg/ml); the cells were titered by spotting aliquots of serial
10-fold dilutions on rifampin-free medium. Each test was carried out
with six separate single-test cell clones. The data were normalized to
108 CFU and expressed as the mean, with P values
determined by the general linear model (25).
Mtz-induced mutation in E. coli:
Rifr.
New mutations to Rifr were
quantified as a measure of Mtz-induced mutation in E. coli
tester strains harboring pGS950 (rdxA+) or the
parent pBSK vector. E. coli strains were grown for 12 h
in LB broth containing Mtz at concentrations of 0, 5, 10, and 15 µg/ml, and aliquots were spread on LB agar containing rifampin (25 µg/ml) and on rifampin-free LB agar. The data were normalized to
108 bacteria and expressed as the mean of triplicate
platings with an error of ±20%.
Mtz-induced mutation in E. coli: lac
papillation assay of specificity.
E. coli tester strains
(CC101, CC103, CC104, CC105, and CC106) harboring either pGS950
(rdxA+) or pBSK control plasmid were grown
overnight in LB broth containing ampicillin (100 µg/ml; Boehringer
Mannheim) at 37°C. The cultures were standardized to an optical
density at 600 nm (OD600) of 1.0, and decimal dilutions
were prepared in phosphate-buffered saline. Dilutions were plated onto
minimal A (MinA) agar medium containing 0.2% glucose, 1 mM
MgSO4 · 7H2O, 500 µg of
phenyl-
-D-galactoside (Sigma) per ml, and 100 µg of
ampicillin per ml (1), supplemented with Mtz at
concentrations of 0, 5, 10, and 15 µg/ml. Immediately before use, the
plates were spread with 40 µl of X-Gal (5-bromo-4-chloro-3-indolyl
-D-galactoside; American Biorganics). Total counts were
determined by dilution and spreading on MinA (1% glucose) agar plates,
which were then incubated for 24 to 36 h. All experiments were
repeated three times, all determinations were performed in triplicate
in each experiment, and the means and standard deviations were
computed. The papillation frequency was determined as the number of
blue (
-galactosidase-positive) papillae per total viable count.
Bystander effect.
To test for Mtz-induced mutation of
bystander cells, a mixture of 108 cells of H. pylori strain 26695 or its rdxA deletion
(Mtzr) derivative 16R plus 108 cells of
E. coli tester strain CC103 at ratios of 1:1, 2:1, and 10:1
was spread on papillation assay plates containing various concentrations of Mtz (0, 5, 10, 15, 32, and 64 µg/ml) as detailed above, except that the plates were incubated under microaerobic conditions. Mtz-induced killing of E. coli was determined
under microaerobic conditions by dilution at each Mtz concentration (presence or absence of H. pylori) by viable count on MinA
medium supplemented with 1% glucose. The papillation medium does not support growth of H. pylori. In a parallel test for
Mtz-induced bystander killing, 108 cells of an
Mtzs H. pylori strain were mixed with 1,000 E. coli cells, and the mixture was spread on a
4-cm2 area of appropriate agar media (L agar and BHI with
serum, plus 0, 10, or 20 µg of Mtz per ml). Incubations were carried
out under microaerobic conditions.
Alkaline gel DNA analysis.
H. pylori strains 26695 (wild type) and 1134 (Mtzs) and rdxA mutant
(Mtzr) derivatives 16R and 1134R, respectively, were grown
overnight on Brucella agar plates containing 7.5% NCS,
collected by centrifugation (7,000 × g), suspended in
Brucella broth, and standardized to an OD600 of
0.25. One milliliter of suspension was added to each 500-ml sidearm
flask containing 100 ml of Brucella broth and NCS. A defined
amount of Mtz was then placed in the side arm of the flask. After being
incubated statically in a microaerobic incubator for 6 h, the
flasks were sealed and placed on a gyratory shaker at 100 rpm for 16 to
20 h at 37°C. Mtz was then tipped from the side arm into the
broth, which was incubated for 30 min with shaking. Aliquots (1 ml) of
the cultures were then harvested and prepared for assessment of DNA
fragmentation. As a control, 100 µl of cell suspension was treated
with 20 mM hydrogen peroxide at 37°C for 15 min to fragment DNA.
E. coli tester strain CC104 harboring either pBSK or its
rdxA+ derivative pGS950 was grown overnight in
MinA broth containing ampicillin (100 µg/ml; Boehringer Mannheim) and
0.5% glucose (1) to a standard OD600 of 0.8. One-milliliter aliquots of culture were treated for 30 min at 37°C
with Mtz at 0, 10, 20, 40, or 100 µg/ml (final concentration).
Agarose plugs were prepared and treated as described elsewhere
(
8), with modifications. Briefly, lysozyme (Sigma) and
proteinase
K (Promega) were added to 100 µl of washed and resuspended
cells
at a final concentration of 1 mg/ml. Following incubation for
15 min at 37°C, 1.2% molten low-melting-point agarose (Eclipse
Molecular Biologicals) and 10% sodium dodecyl sulfate (Sigma)
were
added to final concentrations of 0.5 and 0.6%, respectively.
The
mixture was immediately pipetted into plug molds (Bio-Rad
Laboratories)
and allowed to solidify for 5 to 10 min at 4°C.
The agarose plugs
were then incubated at 55°C for 16 to 22 h in
2 ml of ESP buffer
(pH 9.0), containing 0.5 M EDTA (BDH), 1% (wt/vol)
sodium lauryl
sarcosine (Sigma), and 1 mg of Proteinase per ml.
Following removal of
ESP buffer, the plugs were washed 10 min
at 55°C with sterile
distilled water and four times for 15 min
each at 55°C with TE
buffer, pH 8.0 (10 mM Tris-HCl, 1 mM EDTA),
and then allowed to cool to
4°C.
Alkaline agarose gel electrophoresis generally followed the protocols
in reference
31. Briefly, the agarose plugs were
placed
into the preformed wells of a 0.8% agarose (Vector Biosystems)
gel prepared under alkaline conditions (30 mM NaOH, 10 µM EDTA),
the
wells were sealed in with molten agarose, and then the gel
was
subjected to electrophoresis for 6 h at 25 mV. The gel was
then
neutralized for 1 h in 30 mM NaCl-50 mM Tris-HCl (pH 6.0),
stained for 1 h with ethidium bromide (0.5 µg/ml; Sigma),
destained
in distilled water (2 h), and visualized under UV
light.
 |
RESULTS |
Mtz-induced mutation in H. pylori.
The ability of Mtz to
induce mutation in Mtzs and in Mtzr H. pylori was scored by measuring frequencies of Rifr
mutants in populations of the normally Rifs H. pylori after 3 days growth on plates containing low, partially inhibitory levels of Mtz. The efficiencies of plating (EOP) of wild-type strain 26695 on medium with 2 and 3 µg of Mtz per ml were
about 10
2 and 10
4, respectively, of that on
Mtz-free medium (EOP = 1.0). Growth at these partially lethal Mtz
concentrations increased the Rifr frequencies among
survivors about 6- and 12-fold, respectively (Table
1). In contrast, no significant
stimulation of mutation was detected during an equivalent growth period
on medium with Mtz at 1 µg/ml, a concentration that did not have any
obvious effect on the EOP or colony size of this strain.
The Mtz
r strain 16R (an
rdxA null deletion
mutant derivative of 26695), although fully resistant to 16 µg/ml
(EOP = 1.0), was
partially killed by higher Mtz concentrations
(e.g., EOP = 10
2 and 10
4 at 25 and 32 µg/ml, respectively). These Mtz concentrations were
found to
stimulate mutation to Rif
r about 27- and 166-fold,
respectively (i.e., even more strongly
than had been seen with the
wild-type parent grown with Mtz concentrations
that were partially
lethal to it). In contrast, no such induced
mutation was detected in
cells treated with lower (subinhibitory)
concentrations of Mtz (3, 8, or 16 µg/ml) (Table
1).
Mutant derivatives of strain 16R that are resistant to even higher
concentrations of Mtz (e.g., 64 but not 128 µg/ml [strain
64R]) can
be obtained by forward mutation at
frxA (HP0642 in reference
27; an
rdxA paralog) and other loci
(
17). Although the basis
of this heightened Mtz resistance
and the residual Mtz susceptibility
of these hyperresistant strains are
not fully understood, it is
significant that the growth of such strains
on medium with Mtz
at a partially inhibitory concentration (90 µg/ml)
was also mutagenic.
Again, no stimulation of mutation was detected
after growth with
the concentrations of Mtz that were fully tolerated
by the strain
(8, 16, or 32 µg/ml) (Table
1).
Mtz-induced mutation in E. coli expressing H. pylori rdxA.
The ability of Mtz to induce mutation in E. coli K-12 that had been rendered Mtzs by an expressed
H. pylori rdxA+ gene (pGS950) was scored by
measuring frequencies of Rifr mutants after 12 h of
growth in broth containing low levels of Mtz. Table
2 shows that growth of
rdxA+-containing E. coli with Mtz at
10 and 15 µg/ml in broth culture decreased viability by
10
2 and 10
4, respectively, and increased
the Rifr mutant frequencies ~100- and ~340-fold,
respectively. These Mtz concentrations had no effect on viability or
Rifr frequencies in isogenic control strains that did not
carry rdxA+. Thus, the H. pylori RdxA
nitroreductase renders E. coli highly mutable by Mtz in a
dose-dependent fashion.
Specificity of mutation induced by products of Mtz activation.
To assess the specificity of mutagenesis following Mtz activation, we
scored reversion to Lac+ of a series of isogenic
Lac
strains that differed only in the codon for a
critical residue in the active site of
-galactosidase (essentially
as in reference 4). Prior studies had indicated that
phenotypic reversion from Lac
to Lac+ occurs
by restoration of wild-type sequence in these mutants, not by
suppressor mutations elsewhere in lacZ or in the genome as a
whole. Table 3 shows that growth of these
E. coli lac strains carrying the cloned
rdxA+ gene on medium devised for quantitative
scoring of Lac+ papillae (limiting glucose plus
lactose) that was also supplemented with sublethal concentrations of
Mtz (5 to 15 µg/ml) resulted in dramatic increases in
Lac+ revertant frequencies, whereas no such stimulation was
seen with control E. coli strains grown in parallel. Certain
mutations (CG-to-GC transversions and AT-to-GC transitions) were more
strongly stimulated than others (CG to AT and TA to AT). Although
reversion of even the least responsive allele (TA to GC) seemed to be
stimulated somewhat at the highest usable Mtz concentration (15 µg/ml), this concentration was extremely bactericidal to the E. coli (pGS950) tester strains (EOP = 10
4). In
consequence, the observed increase in Lac+ papillae in this
particular case can be attributed to the effects of bacterial density
and the longer period of growth before exhaustion of the limiting
glucose, and thus more time for Mtz-induced mutation, rather than a
direct mutagenic effect per se on this particular sequence.
Lack of effects on neighboring cells (bystanders).
To test
whether the mutagenic products of Mtz metabolism by H. pylori strains might affect surrounding cells (bystander effect), forward mutation to Lac+ was scored in E. coli
tester strain CC103 in mixed culture experiments (mixing ratios of
H. pylori to E. coli of 1:1 to 10:1; results at
10:1 presented in Table 4). No
Mtz-induced increase in Lac+ reversion frequency or killing
of CC103 grown in mixed cultures with either Mtzs or
Mtzr H. pylori was detected. Similarly, under
conditions more permissive for the growth of H. pylori,
there was no detectable Mtz-induced killing of E. coli
bystanders cocultured with a 105-fold excess of
Mtzs H. pylori (data not presented). Thus, the
mutagenic and bactericidal action of the products of Mtz metabolism
seem to be confined primarily to cells in which they are produced, and
without impact on neighboring cells.
A control in the bystander mutagenesis experiments,
E. coli
CC103 grown microaerobically without
H. pylori cells,
exhibited
Mtz induction of Lac
+ reversion in a
dose-dependent manner (up to ~30-fold [Table
4])
that was not
observed in experiments conducted under aerobic conditions.
There was
also no decrease in viable counts at any of the Mtz
concentrations
tested. These findings suggest that under low oxygen
tensions,
nitroreductases or other redox-active enzymes of
E. coli
activate Mtz, raising the mutation
frequency.
DNA fragmentation as a measure of other genetic damage resulting
from Mtz activation.
To test for DNA damage that might be distinct
from Mtz-induced premutagenic lesions, isogenic Mtzs and
Mtzr H. pylori strains were treated for 30 min
in Brucella broth with different concentrations of Mtz or,
for comparison, with 20 mM H2O2, an oxidant
that causes DNA fragmentation (31). Figure 1A shows that treatment of the
Mtzs strain 26695 with increasing concentrations of Mtz (5 to 15 µg/ml) caused dose-dependent DNA fragmentation. A similar
result was obtained with Mtzs strain 1134, except that DNA
fragmentation was evident at lower Mtz concentrations (Fig. 1C).
Analysis of DNA fragmentation on nondenaturing agarose gels indicated
that most of the DNA fragmentation observed using alkaline (denaturing)
gels resulted from single- rather than double-strand breakage (data not
presented). The Mtzr strains 16R (Fig. 1B) and 1134R (Fig.
1D) exhibited DNA breakage only at the higher Mtz concentrations that
were at least partially lethal to them (e.g.,
10 µg/ml for 16R and
25 µg/ml for 1134R). Since 16R and 1134R contain loss-of-function
mutations in rdxA (9, 17), additional
redox-active enzymes must also act on Mtz at high concentrations,
generating products that also contribute to the observed DNA breakage
and lethality.

View larger version (91K):
[in this window]
[in a new window]
|
FIG. 1.
Mtz-induced DNA fragmentation of MtzR and MtzS strains
of H. pylori. Mtzs and Mtzr strains
of H. pylori were challenged with various concentrations of
Mtz for 30 min as described in the text. The bacteria were suspended
and lysed in agarose plugs, and agarose gels were run under alkaline
conditions to display the extent of DNA fragmentation of denatured
genomic DNA. Bacteria were treated with hydrogen peroxide (20 mM) for
15 min (positive controls). Mtz was used at 0, 2, 5, 10, 15, 25, 50, 100, and 200 µg/ml. (A) H. pylori strain 26695 (Mtzs); (B) its rdxA deletion derivative strain
16R (Mtzr); (C) strain 1134 (Mtzs); (D) strain
1134R (Mtzr).
|
|
Further demonstration that Mtz activation causes DNA fragmentation was
obtained with
E. coli tester strains carrying a cloned
rdxA+ gene. Figure
2 shows that Mtz (5 to 100 µg/ml)
caused significant
DNA fragmentation when
rdxA+
was present (pGS950), whereas no such fragmentation was observed
in
E. coli lacking
rdxA+, a strain fully
resistant to Mtz.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 2.
Mtz-induced DNA fragmentation of E. coli
strains carrying rdxA of H. pylori. E. coli
strain CC104 containing either pBSK (control) or pGS950
(rdxA+) was grown in the presence of Mtz;
bacteria were suspended and lysed in agarose plugs and electrophoresed
as described in the legend to Fig. 1 and detailed in the text. Hydrogen
peroxide was added at 20 mM as a positive control. The distinct bands
noted in the various lanes are of plasmid DNA.
|
|
 |
DISCUSSION |
Here we have shown that the potent antimicrobial drug Mtz can be
highly mutagenic for H. pylori and for E. coli
strains carrying rdxA+, the H. pylori
gene whose product is needed for efficient Mtz activation. Mtz is also
mutagenic for Mtzr strains of H. pylori
containing null mutations in rdxA when the drug is used at
concentrations that are considered therapeutic for Mtzs
strains (i.e., in combination therapies) but only partially toxic for
Mtzr strains. Products of Mtz activation primarily induce
single-strand DNA breakage, with extensive fragmentation occurring at
Mtz levels near or higher than the MIC. Reversion tests with E. coli rdxA+-carrying tester strains revealed mostly
CG-to-GC transversions and AT-to-GC transitions (with other base
substitutions at lower frequencies) with the alleles studied. This
suggests the participation of nitro, nitroso, and hydroxylamine
intermediates of Mtz, perhaps each differing in reactivity or base
specificity (7, 9, 18). Taken together, these studies
indicate that Mtz therapy probably induces, as well as selects for, the
loss-of-function mutations in rdxA that are characteristic
of every Mtzr clinical isolate tested to date (5, 9,
15-17, 26).
It is striking that Mtz was more mutagenic for Mtzr than
Mtzs H. pylori strains (27- to 166-fold versus
6- to 12-fold, respectively) when used at levels that inhibit growth to
similar extents. The more efficient mutagenesis in Mtzr
strains might reflect (i) the high specific activity of RdxA for Mtz
(e.g., mutagenic and lethal concentrations are similar), (ii) lower
specific activities (substrate specificity for Mtz) of other as yet
unknown Mtz-activating enzymes, (iii) changes in the metabolic capacity
in response to Mtz (13), and/or (iv) changes in balances of
enzymes affecting the fidelity of DNA replication or the efficiencies
of repair. That mutagenesis and cell killing were observed in simple
rdxA mutants illustrates that Mtz can be activated by other
cellular enzymes, albeit less efficiently than by RdxA. One such enzyme
is FrxA, a flavin nitroreductase of H. pylori
(9), whose inactivation together with that of RdxA results
in increased Mtz resistance (17). Our finding that Mtz is
also mutagenic for hyperresistant (rdxA frxA) strains
indicates that additional enzymes must also participate to some extent. These additional redox-active enzymes may be quite widespread, since
Mtz in high concentration (>150 µg/ml) is toxic for many bacterial
species that are considered resistant clinically (7). In
general, Mtz toxicity is increased for most bacteria and mammalian cells under hypoxic conditions where nitroreductases, ferredoxins, flavodoxins, cytochrome P450, and nonspecific redox-active components contribute more efficiently to Mtz activation (7, 13, 28). Mutational inactivation of genes encoding these additional Mtz activating enzymes most likely accounts for the stepwise appearance of
hyper-Mtzr mutants of H. pylori, although
mutations affecting other functions such as DNA repair may also
contribute to some extent.
The different efficiencies of Mtz-induced DNA breakage in
Mtzs and Mtzr strains of H. pylori
can also be attributed to loss of function of the RdxA nitroreductase
in Mtzr strains. Findings that Mtz-induced DNA breakage and
mutation were greatest at levels near the MIC in E. coli
strains expressing rdxA+ support this
interpretation. In the absence of RdxA activity, E. coli is
extremely resistant to Mtz (>250 µg/ml), indicating that its own
nitroreductases do not contribute appreciably to Mtz activation during
growth at normal atmosphere in the concentration range used. However,
under microaerobic conditions (6% oxygen), Mtz is more mutagenic for
E. coli (Tables 3 and 4), suggesting that its
nitroreductases or other redox-active enzymes can metabolize this drug.
These Mtz-activating enzymes may be induced to higher levels in
response to oxygen-limiting conditions (metabolic transition to a more
fermentative capacity) or may participate more substantially in removal
of reducing equivalents to alternate electron acceptors such as Mtz.
Our studies further showed that in hyper-Mtzr H. pylori strains, which contain mutations in a gene(s) in addition to rdxA and frxA, the efficiency of DNA breakage
requires much higher Mtz concentrations. We have shown a correlation
between MIC of Mtz for a particular strain and the efficiency of DNA
breakage after exposure to Mtz. In this regard, DNA fragmentation was
seen at lower Mtz concentrations for strain 26695 16R
(rdxA
), which tolerates 16 µg/ml, than for strain
1134R, which tolerates twice that level (32 µg/ml).
In vitro studies of the interactions of reduced products of Mtz with
DNA have indicated that DNA fragmentation is favored over base
modification (7). In vivo, Mtz is said to cause more base
pair substitution than DNA fragmentation in enteric bacteria (2) but more DNA fragmentation in highly susceptible
anaerobic bacteria (7, 28, 29). In one study of selected
gene targets, Mtz induced exclusively GC-to-CG transversion mutations
in Bacteroides fragilis (29). Here we found
CG-to-GC transversions and AT-to-GC transitions to be most common in
E. coli tester strains expressing rdxA+, although Mtz induced other substitutions
at concentrations that would also cause DNA fragmentation. These base
substitution differences are not due to variation among tester strains
since these strains showed similar frequencies of mutation to
Rifr. The high frequency of mutation seen at the highest
concentrations of Mtz in each of the E. coli tester strains
may be due to activation of the error-prone SOS repair system, a repair
mechanism that is lacking in H. pylori (27).
We suggest that Mtz-induced DNA strand breakage, like base substitution
mutagenesis, is significant biologically: DNA breakage should stimulate
recombination between duplicate and divergent sequences (of which there
are many in H. pylori) within a given genome and perhaps
recombination between different strains as well. Repair of Mtz-induced
DNA breaks should also promote the metastable turning on and off of
contingency genes, identified by their distinctive repetitive sequences
(24), and more generally induce frameshift mutations
(21) such as we and others have found after Mtz treatment
(9, 15). DNA lesions not involving DNA breakage may be
responsible for most of the base substitutions scored here. Mutation
and genetic recombination each contribute to the genome diversity that
can facilitate adaptation to new and changing conditions in human
hosts, the development of resistance to clinically useful drugs,
and the evolution of virulence. The emergence of resistance to
Mtz, selected and possibly induced by this drug during H. pylori infection, has been documented in an animal infection model
(16). NH2-containing therapies, in addition to
contributing to Mtz hyperresistance, may also induce resistance to
other clinically useful drugs (secondary antibiotic resistance). By
extrapolation, Mtz therapies might also be mutagenic for the resident
intestinal flora (which also live in microaerobic and anaerobic
environments) and thereby similarly speed the emergence of drug
resistance and other evolutionary changes in them.
The biologically active products of Mtz metabolism are considered to be
short-lived and thus perhaps unlikely to act on cells other than those
in which they are produced (7). It was therefore comforting
from a public health perspective that no Mtz-induced killing or
mutagenesis of adjacent bystander E. coli cells was detected
in these experiments. Thus, the products of Mtz metabolism by H. pylori probably do not interact synergistically with reactive oxygen and nitrogen metabolites generated in the host inflammatory response that are suspected of contributing to gastric pathologies and
cancer (14, 22). As counterpoint, we wish to consider the
possibility that a generic function for the nitroreductases studied
here is in the catabolism (detoxification) of nitrated aromatic amino
acids and other reactive metabolites that are generated during
inflammation, and thus of differences between Mtzr and
Mtzs strains in virulence or in speed of adaptation to host defenses.
 |
ACKNOWLEDGMENTS |
We thank Jeffrey H. Miller for providing tester strains, Rob
Bethune for technical assistance with DNA fragmentation studies, Bill
Shannon for carrying out statistical analyses, an anonymous reviewer
for suggesting the bystander experiment, and Hans Kusters and Jetta
Bijlsma for helpful discussions.
This work was supported by grants from MRC (R-14292), from AstraZeneca
Canada, and from Romark Laboratories to P.S.H. and by Public Health
Service (NIH) grants AI38166 and DK53727 to D.E.B.
 |
FOOTNOTES |
*
Corresponding author. Present address: Anti Infectives
Research Division, SmithKline Beecham Pharmaceuticals, 1250 Collegeville Road, Collegeville, PA 19426. Phone: (610) 917-6010. Fax:
(610) 917-7901. E-mail: Paul_2_Hoffman{at}sbphrd.com or
phoffman{at}tupdean2.med.dal.ca.
 |
REFERENCES |
| 1.
|
Ausubel, F. M., et al. (ed.).
1998.
Current protocols in molecular biology, vol. 1. , p. 1.1.1.
Wiley Interscience, New York, N.Y.
|
| 2.
|
Chin, J. B.,
D. M. K. Sheinin, and A. M. Rauth.
1978.
Screening for the mutagenicity of nitro-group containing hypoxic cell radiosensitizers using Salmonella typhimurium strains TA100 and TA98.
Mutat. Res.
58:1-10[CrossRef][Medline].
|
| 3.
|
Correa, P.
1996.
Helicobacter pylori and gastric cancer: state of the art.
Epidemiol. Biomarkers Prev.
5:477-481.
|
| 4.
|
Cupples, C. G., and J. H. Miller.
1989.
A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions.
Proc. Natl. Acad. Sci. USA
86:5345-5349[Abstract/Free Full Text].
|
| 5.
|
Debets-Ossenkopp, Y. J.,
R. G. Pot,
D. J. van Westerloo,
A. Goodwin,
C. M. Vandenbroucke-Grauls,
D. E. Berg,
P. S. Hoffman, and J. G. Kusters.
1999.
Insertion of mini-IS605 and deletion of adjacent sequences in the nitroreductase (rdxA) gene cause metronidazole resistance in Helicobacter pylori NCTC11637.
Antimicrob. Agents Chemother.
43:2657-2662[Abstract/Free Full Text].
|
| 6.
|
Dunn, B. E.,
H. Cohen, and M. J. Blaser.
1997.
Helicobacter pylori.
Clin. Microbiol. Rev.
10:720-741[Abstract].
|
| 7.
|
Edwards, D. I.
1993.
Nitroimidazole drugs action and resistance mechanisms. I. Mechanisms of action.
J. Antimicrob. Chemother.
31:9-20[Free Full Text].
|
| 8.
|
Gauton, R. K.
1997.
Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day.
J. Clin. Microbiol.
35:2977-2980[Abstract].
|
| 9.
|
Goodwin, A.,
D. Kersulyte,
G. Sisson,
S. J. O. Veldhuyzen van Zanten,
D. E. Berg, and P. S. Hoffman.
1998.
Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase.
Mol. Microbiol.
28:383-393[CrossRef][Medline].
|
| 10.
|
Glupczynski, Y., and A. Burette.
1990.
Drug therapy for Helicobacter pylori infection: problems and pitfalls.
Am. J. Gastroenterol.
85:1545-1551[Medline].
|
| 11.
|
Heep, M.,
D. Beck,
E. Bayerdorffer, and N. Lehn.
1999.
Rifampin and rifabutin resistance mechanism in Helicobacter pylori.
Antimicrob. Agents Chemother.
43:1497-1499[Abstract/Free Full Text].
|
| 12.
|
Hoffman, P. S.
1999.
Antibiotic resistance mechanisms of Helicobacter pylori.
Can. J. Gastroenterol.
13:243-249[Medline].
|
| 13.
|
Hoffman, P. S.,
A. Goodwin,
J. Johnsen,
K. Magee, and S. J. O. Veldhuyzen van Zanten.
1996.
Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance.
J. Bacteriol.
178:4822-4829[Abstract/Free Full Text].
|
| 14.
|
Isaacson, P. G.
1999.
Gastric MALT lymphoma: from concept to cure.
Ann. Oncol.
10:637-645[Abstract/Free Full Text].
|
| 15.
|
Jenks, P. J.,
R. L. Ferrero, and A. Labinge.
1999.
The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori.
J. Antimicrob. Chemother.
43:753-758[Abstract/Free Full Text].
|
| 16.
|
Jenks, P. J.,
A. Labigne, and R. L. Ferrero.
1999.
Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice.
Antimicrob. Agents Chemother.
43:777-781[Abstract/Free Full Text].
|
| 17.
|
Jeong, J.-Y.,
A. K. Mukhopadhyay,
D. Dailidiene,
Y. Wang,
B. Velapatiño,
R. H. Gilman,
A. J. Parkinson,
G. B. Nair,
B. C. Y. Wong,
S. K. Lam,
R. Mistry,
I. Segal,
Y. Yuan,
H. Gao,
T. Alarcon,
M. L. Brea,
Y. Ito,
D. Kersulyte,
H.-K. Lee,
Y. Gong,
A. Goodwin,
P. S. Hoffman, and D. E. Berg.
2000.
Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level metronidazole resistance in Helicobacter pylori.
J. Bacteriol.
182:5082-5090[Abstract/Free Full Text].
|
| 18.
|
Lindmark, D. G., and M. Muller.
1976.
Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles.
Antimicrob. Agents Chemother.
10:476-482[Abstract/Free Full Text].
|
| 19.
|
Lockerby, D. L.,
H. R. Rabin, and E. J. Laishley.
1985.
Role of the phosphoroclastic reaction of Clostridium pasteurianum in the reduction of metronidazole.
Antimicrob. Agents Chemother.
27:863-867[Abstract/Free Full Text].
|
| 20.
|
Malfertheiner, P.,
F. Megraud, and C. O'Morain.
1997.
Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report.
Gut
41:8-13[Abstract/Free Full Text].
|
| 21.
|
McKenzie, G. J.,
R. S. Harris,
P. L. Lee, and S. M. Rosenberg.
2000.
The SOS response regulates adaptive mutation.
Proc. Natl. Acad. Sci. USA
97:6646-6651[Abstract/Free Full Text].
|
| 22.
|
Murakami, K.,
T. Fujioka,
T. Okimoto,
Y. Mitsuishi,
T. Oda,
A. Nishizono, and M. Nasu.
1999.
Analysis of p53 gene mutations in Helicobacter pylori-associated gastritis mucosa in endoscopic biopsy specimens.
Scand. J. Gastroenterol.
34:474-477[CrossRef][Medline].
|
| 23.
|
Rasmussen, B. A.,
K. Bush, and F. P. Tally.
1997.
Antimicrobial resistance in anaerobes.
Clin. Infect. Dis.
24:S110-S120.
|
| 24.
|
Saunders, N. J.,
J. F. Peden,
D. W. Hood, and E. R. Moxon.
1998.
Simple sequence repeats in the Helicobacter pylori genome.
Mol. Microbiol.
27:1091-1098[CrossRef][Medline].
|
| 25.
|
Searle, S. R.
1971.
Linear models. J.
Wiley & Sons, New York, N.Y.
|
| 26.
|
Tankovic, J.,
D. Lamarque,
J.-C. Delchier,
C.-J. Soussy,
A. Labinge, and P. J. Jenks.
2000.
Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori.
Antimicrob. Agents Chemother.
44:608-613[Abstract/Free Full Text].
|
| 27.
|
Tomb, J. F.,
O. White,
A. R. Kerlavage,
R. A. Clayton,
G. G. Sutton,
R. D. Fleischmann,
K. Ketchum,
H. Klenk,
S. Gill,
B. Dougherty,
K. Nelson,
J. Quackenbush,
L. Zhou,
E. Kirkness,
S. Peterson,
B. Loftus,
D. Richardson,
R. Dodson,
H. Khalak,
A. Glodek,
K. McKenney,
L. Fitzegerald,
N. Lee,
M. Adams,
E. Hickey,
D. Berg,
J. Gocayne,
T. Utterback,
J. Peterson,
J. Kelley,
M. Cotton,
J. Weidman,
C. Fujii,
C. Bowman,
L. Watthey,
E. Wallin,
W. Hayes,
M. Borodovsky,
P. Karp,
H. Smith,
C. Fraser, and J. Venter.
1997.
The complete genome sequence of the gastric pathogen Helicobacter pylori.
Nature
388:539-547[CrossRef][Medline].
|
| 28.
|
Townson, S. M.,
P. F. L. Boreham,
P. Upcroft, and J. A. Upcroft.
1994.
Resistance to the nitroheterocyclic drugs.
Acta Trop.
56:173-194[CrossRef][Medline].
|
| 29.
|
Trinh, S., and G. Reysset.
1998.
Mutagenic action of 5-nitroimidazoles: in vivo induction of GC CG transversion in two Bacteroides fragilis reporter genes.
Mutat. Res.
398:55-65[Medline].
|
| 30.
|
Veldhuyzen van Zanten, S. J. O.,
P. M. Sherman, and R. H. Hunt.
1997.
Helicobacter pylori: new developments and treatments.
Can. Med. Assoc. J.
156:1565-1574[Abstract].
|
| 31.
|
Zirkle, R. E., and N. R. Krieg.
1996.
Development of a method based on alkaline gel electrophoresis for estimation of oxidative damage to DNA in Escherichia coli.
J. Appl. Bacteriol.
81:133-138[Medline].
|
Journal of Bacteriology, September 2000, p. 5091-5096, Vol. 182, No. 18
0021-9193/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kaakoush, N. O., Asencio, C., Megraud, F., Mendz, G. L.
(2009). A Redox Basis for Metronidazole Resistance in Helicobacter pylori. Antimicrob. Agents Chemother.
53: 1884-1891
[Abstract]
[Full Text]
-
Stanton, T. B., Humphrey, S. B., Sharma, V. K., Zuerner, R. L.
(2008). Collateral Effects of Antibiotics: Carbadox and Metronidazole Induce VSH-1 and Facilitate Gene Transfer among Brachyspira hyodysenteriae Strains. Appl. Environ. Microbiol.
74: 2950-2956
[Abstract]
[Full Text]
-
St. Maurice, M., Cremades, N., Croxen, M. A., Sisson, G., Sancho, J., Hoffman, P. S.
(2007). Flavodoxin:Quinone Reductase (FqrB): a Redox Partner of Pyruvate:Ferredoxin Oxidoreductase That Reversibly Couples Pyruvate Oxidation to NADPH Production in Helicobacter pylori and Campylobacter jejuni. J. Bacteriol.
189: 4764-4773
[Abstract]
[Full Text]
-
Hoffman, P. S., Sisson, G., Croxen, M. A., Welch, K., Harman, W. D., Cremades, N., Morash, M. G.
(2007). Antiparasitic Drug Nitazoxanide Inhibits the Pyruvate Oxidoreductases of Helicobacter pylori, Selected Anaerobic Bacteria and Parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother.
51: 868-876
[Abstract]
[Full Text]
-
Tan, S., Fraley, C. D., Zhang, M., Dailidiene, D., Kornberg, A., Berg, D. E.
(2005). Diverse Phenotypes Resulting from Polyphosphate Kinase Gene (ppk1) Inactivation in Different Strains of Helicobacter pylori. J. Bacteriol.
187: 7687-7695
[Abstract]
[Full Text]
-
Zaleski, P., Piekarowicz, A.
(2004). Characterization of a dam mutant of Haemophilus influenzae Rd. Microbiology
150: 3773-3781
[Abstract]
[Full Text]
-
Nahar, S., Mukhopadhyay, A. K., Khan, R., Ahmad, M. M., Datta, S., Chattopadhyay, S., Dhar, S. C., Sarker, S. A., Engstrand, L., Berg, D. E., Nair, G. B., Rahman, M.
(2004). Antimicrobial Susceptibility of Helicobacter pylori Strains Isolated in Bangladesh. J. Clin. Microbiol.
42: 4856-4858
[Abstract]
[Full Text]
-
Diniz, C. G., Farias, L. M., Carvalho, M. A. R., Rocha, E. R., Smith, C. J.
(2004). Differential gene expression in a Bacteroides fragilis metronidazole-resistant mutant. J Antimicrob Chemother
54: 100-108
[Abstract]
[Full Text]
-
Loughlin, M. F., Barnard, F. M., Jenkins, D., Sharples, G. J., Jenks, P. J.
(2003). Helicobacter pylori Mutants Defective in RuvC Holliday Junction Resolvase Display Reduced Macrophage Survival and Spontaneous Clearance from the Murine Gastric Mucosa. Infect. Immun.
71: 2022-2031
[Abstract]
[Full Text]
-
Wang, W H, Wong, W M, Dailidiene, D, Berg, D E, Gu, Q, Lai, K C, Lam, S K, Wong, B C Y
(2003). Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut
52: 490-495
[Abstract]
[Full Text]
-
Vidakovic, M., Crossnoe, C. R., Neidre, C., Kim, K., Krause, K. L., Germanas, J. P.
(2003). Reactivity of Reduced [2Fe-2S] Ferredoxins Parallels Host Susceptibility to Nitroimidazoles. Antimicrob. Agents Chemother.
47: 302-308
[Abstract]
[Full Text]
-
Dailidiene, D., Bertoli, M. T., Miciuleviciene, J., Mukhopadhyay, A. K., Dailide, G., Pascasio, M. A., Kupcinskas, L., Berg, D. E.
(2002). Emergence of Tetracycline Resistance in Helicobacter pylori: Multiple Mutational Changes in 16S Ribosomal DNA and Other Genetic Loci. Antimicrob. Agents Chemother.
46: 3940-3946
[Abstract]
[Full Text]
-
Sisson, G., Goodwin, A., Raudonikiene, A., Hughes, N. J., Mukhopadhyay, A. K., Berg, D. E., Hoffman, P. S.
(2002). Enzymes Associated with Reductive Activation and Action of Nitazoxanide, Nitrofurans, and Metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother.
46: 2116-2123
[Abstract]
[Full Text]
-
Prazeres Magalhaes, P., de Magalhaes Queiroz, D. M., Campos Barbosa, D. V., Aguiar Rocha, G., Nogueira Mendes, E., Santos, A., Valle Correa, P. R., Camargos Rocha, A. M., Martins Teixeira, L., Affonso de Oliveira, C.
(2002). Helicobacter pylori Primary Resistance to Metronidazole and Clarithromycin in Brazil. Antimicrob. Agents Chemother.
46: 2021-2023
[Abstract]
[Full Text]
-
Trieber, C. A., Taylor, D. E.
(2002). Mutations in the 16S rRNA Genes of Helicobacter pylori Mediate Resistance to Tetracycline. J. Bacteriol.
184: 2131-2140
[Abstract]
[Full Text]
-
Purkayastha, A., McCue, L. A., McDonough, K. A.
(2002). Identification of a Mycobacterium tuberculosis Putative Classical Nitroreductase Gene Whose Expression Is Coregulated with That of the acr Gene within Macrophages, in Standing versus Shaking Cultures, and under Low Oxygen Conditions. Infect. Immun.
70: 1518-1529
[Abstract]
[Full Text]
-
Kwon, D. H., Hulten, K., Kato, M., Kim, J. J., Lee, M., El-Zaatari, F. A. K., Osato, M. S., Graham, D. Y.
(2001). DNA Sequence Analysis of rdxA and frxA from 12 Pairs of Metronidazole-Sensitive and -Resistant Clinical Helicobacter pylori Isolates. Antimicrob. Agents Chemother.
45: 2609-2615
[Abstract]
[Full Text]
-
Jeong, J.-Y., Mukhopadhyay, A. K., Akada, J. K., Dailidiene, D., Hoffman, P. S., Berg, D. E.
(2001). Roles of FrxA and RdxA Nitroreductases of Helicobacter pylori in Susceptibility and Resistance to Metronidazole. J. Bacteriol.
183: 5155-5162
[Abstract]
[Full Text]
-
Seyler, R. W. Jr., Olson, J. W., Maier, R. J.
(2001). Superoxide Dismutase-Deficient Mutants of Helicobacter pylori Are Hypersensitive to Oxidative Stress and Defective in Host Colonization. Infect. Immun.
69: 4034-4040
[Abstract]
[Full Text]
-
Kim, J. J., Reddy, R., Lee, M., Kim, J. G., El-Zaatari, F. A. K., Osato, M. S., Graham, D. Y., Kwon, D. H.
(2001). Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother
47: 459-461
[Abstract]
[Full Text]
-
Wang, G., Wilson, T. J. M., Jiang, Q., Taylor, D. E.
(2001). Spontaneous Mutations That Confer Antibiotic Resistance in Helicobacter pylori. Antimicrob. Agents Chemother.
45: 727-733
[Abstract]
[Full Text]
-
Jeong, J.-Y., Berg, D. E.
(2000). Mouse-Colonizing Helicobacter pylori SS1 Is Unusually Susceptible to Metronidazole Due to Two Complementary Reductase Activities. Antimicrob. Agents Chemother.
44: 3127-3132
[Abstract]
[Full Text]
-
Jeong, J.-Y., Mukhopadhyay, A. K., Dailidiene, D., Wang, Y., Velapatiño, B., Gilman, R. H., Parkinson, A. J., Nair, G. B., Wong, B. C. Y., Lam, S. K., Mistry, R., Segal, I., Yuan, Y., Gao, H., Alarcon, T., Brea, M. L., Ito, Y., Kersulyte, D., Lee, H.-K., Gong, Y., Goodwin, A., Hoffman, P. S., Berg, D. E.
(2000). Sequential Inactivation of rdxA (HP0954) and frxA (HP0642) Nitroreductase Genes Causes Moderate and High-Level Metronidazole Resistance in Helicobacter pylori. J. Bacteriol.
182: 5082-5090
[Abstract]
[Full Text]